CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,510,022 | +89.9% | 1,530,263 | +15.0% | 1.54% | +161.5% |
| Q2 2023 | $23,971,339 | +12.2% | 1,330,263 | 0.0% | 0.59% | -14.7% |
| Q1 2023 | $21,364,024 | -12.2% | 1,330,263 | 0.0% | 0.69% | -7.2% |
| Q4 2022 | $24,343,813 | -6.8% | 1,330,263 | 0.0% | 0.74% | -3.9% |
| Q3 2022 | $26,126,000 | +5.3% | 1,330,263 | 0.0% | 0.77% | -9.9% |
| Q2 2022 | $24,809,000 | +43.0% | 1,330,263 | +68.3% | 0.86% | +57.6% |
| Q1 2022 | $17,345,000 | +3.4% | 790,209 | +33.9% | 0.54% | +1.7% |
| Q4 2021 | $16,767,000 | +11.3% | 590,169 | -31.4% | 0.53% | -52.0% |
| Q2 2020 | $15,064,000 | +192.8% | 859,802 | +145.7% | 1.11% | +107.1% |
| Q1 2020 | $5,145,000 | – | 350,000 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 623,819 | $11,336,501 | 9.41% |
| Finepoint Capital LP | 822,745 | $15,056 | 4.87% |
| Bain Capital Life Sciences Investors, LLC | 2,305,558 | $42,192 | 4.72% |
| Opaleye Management Inc. | 732,000 | $13,395,600 | 4.66% |
| 5AM Venture Management, LLC | 862,286 | $15,779,834 | 4.24% |
| SPHERA FUNDS MANAGEMENT LTD. | 671,644 | $12,291,085 | 2.64% |
| First Light Asset Management, LLC | 1,329,313 | $24,326,428 | 2.26% |
| BRAIDWELL LP | 3,469,674 | $63,495,034 | 2.13% |
| BVF INC/IL | 2,736,613 | $50,080,018 | 2.11% |
| Perceptive Advisors | 4,039,276 | $73,918,751 | 2.08% |